{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T10:29:27Z","timestamp":1783247367961,"version":"3.54.6"},"reference-count":117,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2017\/25588-1"],"award-info":[{"award-number":["2017\/25588-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2016\/18715-4"],"award-info":[{"award-number":["2016\/18715-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2014\/10068-4"],"award-info":[{"award-number":["2014\/10068-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2020\/00098-7"],"award-info":[{"award-number":["2020\/00098-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Proteomics"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jprot.2020.103813","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T02:39:37Z","timestamp":1590460777000},"page":"103813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients"],"prefix":"10.1016","volume":"224","author":[{"given":"Sheila","family":"Garcia-Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benilton S.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Martins-de-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jprot.2020.103813_bb0005","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archpsyc.60.12.1187","article-title":"Schizophrenia as a complex trait","volume":"60","author":"Sullivan","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.schres.2008.07.020","article-title":"Schizophrenia, \u201cjust the facts\u201d: what we know in 2008. Part 3: neurobiology","volume":"106","author":"Keshavan","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0015","unstructured":"WHO. World Health Organization. (2019). Schizophrenia. Retrieved from: http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\/. (2019) Available at: http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\/."},{"key":"10.1016\/j.jprot.2020.103813_bb0020","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0025","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/schbul\/sbn005","article-title":"Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features","volume":"35","author":"Rabinowitz","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jprot.2020.103813_bb0030","doi-asserted-by":"crossref","DOI":"10.1007\/s11126-019-09633-4","article-title":"Quality of life in schizophrenia: A meta-analysis of comparative studies","author":"Dong","year":"2019","journal-title":"Psychiatr. Q"},{"key":"10.1016\/j.jprot.2020.103813_bb0035","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1176\/appi.ajp.2017.16091016","article-title":"The long-term effects of antipsychotic medication on clinical course in schizophrenia","volume":"174","author":"Goff","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2010.05.025","article-title":"Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future","volume":"122","author":"Tandon","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jprot.2020.103813_bb0050","series-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","author":"Bymaster","year":"1996"},{"key":"10.1016\/j.jprot.2020.103813_bb0055","first-page":"749","article-title":"Olanzapine approved for the acute treatment of schizophrenia or manic\/mixed episodes associated with bipolar I disorder in adolescent patients","volume":"6","author":"Maloney","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jprot.2020.103813_bb0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0065","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1097\/00004714-199502001-00008","article-title":"Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia","volume":"15","author":"Klieser","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jprot.2020.103813_bb0070","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jprot.2020.103813_bb0075","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0269881114562090","article-title":"\u201cFirst do no harm.\u201d A systematic review of the prevalence and management of antipsychotic adverse effects","volume":"29","author":"Young","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jprot.2020.103813_bb0080","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a Nationwide cohort of 29 823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jprot.2020.103813_bb0085","series-title":"Proteins. United Kin","author":"Putnam","year":"1963"},{"key":"10.1016\/j.jprot.2020.103813_bb0090","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","article-title":"The human plasma proteome: history, character, and diagnostic prospects","volume":"1","author":"Anderson","year":"2002","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jprot.2020.103813_bb0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/acs.analchem.5b04230","article-title":"Bottom-up proteomics (2013\u20132015): keeping up in the era of systems biology","volume":"88","author":"Mayne","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jprot.2020.103813_bb0100","series-title":"The emergence of point-of-care blood- based biomarker testing for psychiatric disorders\u202f: enabling personalized medicine","author":"Guest","year":"2016"},{"key":"10.1016\/j.jprot.2020.103813_bb0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nbt0196-61","article-title":"From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and Arnino acid analysis","volume":"14","author":"Wilkins","year":"1996","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jprot.2020.103813_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1590\/S0101-60832012005000005","article-title":"Biomarker blood tests for diagnosis and management of mental disorders: focus on schizophrenia","volume":"40","author":"Bahn","year":"2012","journal-title":"Rev Psiqiatr Cl\u00edn"},{"key":"10.1016\/j.jprot.2020.103813_bb0115","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1074\/mcp.R200007-MCP200","article-title":"The human plasma proteome","volume":"1","author":"Anderson","year":"2002","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.jprot.2020.103813_bb0120","series-title":"Affinity Depletion of Plasma and Serum for Mass Spectrometry-Based Proteome Analysis. , eds. M. Zhou, T","author":"Jaros","year":"2013"},{"key":"10.1016\/j.jprot.2020.103813_bb0125","first-page":"3","article-title":"A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study","volume":"1","author":"Martins-de-Souza","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jprot.2020.103813_bb0130","doi-asserted-by":"crossref","first-page":"15050","DOI":"10.1038\/npjschz.2015.50","article-title":"Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical response","volume":"1","author":"Martins-de-Souza","year":"2015","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.jprot.2020.103813_bb0135","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-018-4835-6","article-title":"Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study","volume":"235","author":"Zhang","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jprot.2020.103813_bb0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bbi.2015.10.019","article-title":"Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients","volume":"52","author":"Tomasik","year":"2016","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jprot.2020.103813_bb0145","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2217\/bmm.13.83","article-title":"The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients","volume":"8","author":"Guest","year":"2014","journal-title":"Biomark. Med"},{"key":"10.1016\/j.jprot.2020.103813_bb0150","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fpsyt.2018.00209","article-title":"Blood-based Lipidomics approach to evaluate biomarkers associated with response to olanzapine, Risperidone, and Quetiapine treatment in schizophrenia patients","volume":"9","author":"Aquino","year":"2018","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jprot.2020.103813_bb0155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2016.01.015","article-title":"Contributions of immunoaffinity chromatography to deep proteome profiling of human biofluids","volume":"1021","author":"Wu","year":"2016","journal-title":"J. Chromatogr. B Analyt Technol. Biomed Life Sci."},{"key":"10.1016\/j.jprot.2020.103813_bb0160","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jchromb.2013.09.008","article-title":"Performance evaluation of affinity ligands for depletion of abundant plasma proteins","volume":"939","author":"Kullolli","year":"2013","journal-title":"J. Chromatogr. B Analyt Technol. Biomed Life Sci."},{"key":"10.1016\/j.jprot.2020.103813_bb0165","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.talanta.2017.03.091","article-title":"Depleting high-abundant and enriching low-abundant proteins in human serum: an evaluation of sample preparation methods using magnetic nanoparticle, chemical depletion and immunoaffinity techniques","volume":"170","author":"de Jesus","year":"2017","journal-title":"Talanta"},{"key":"10.1016\/j.jprot.2020.103813_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-3-319-52479-5_15","article-title":"Identifying biomarker candidates in the blood plasma or serum proteome","volume":"974","author":"Garcia","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jprot.2020.103813_bb0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-1-4939-6730-8_16","article-title":"Depletion of highly abundant proteins of the human blood plasma: applications in proteomics studies of psychiatric disorders","volume":"1546","author":"Garcia","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jprot.2020.103813_bb0180","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/sscp.201900057","article-title":"Blood plasma high abundant protein depletion unintentionally carries over 100 proteins","volume":"2","author":"Silva-Costa","year":"2019","journal-title":"Sep. Sci. Plus"},{"key":"10.1016\/j.jprot.2020.103813_bb0185","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/pmic.200800562","article-title":"The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependant LC-MS\/MS","volume":"9","author":"Geromanos","year":"2009","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2020.103813_bb0190","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/pmic.200800564","article-title":"Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures","volume":"9","author":"Li","year":"2009","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2020.103813_bb0195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jprot.2020.103813_bb0200","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in ingenuity pathway analysis","volume":"30","author":"Kr\u00e4mer","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jprot.2020.103813_bb0205","doi-asserted-by":"crossref","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","article-title":"The reactome pathway knowledgebase","volume":"46","author":"Fabregat","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0210","doi-asserted-by":"crossref","first-page":"W566","DOI":"10.1093\/nar\/gkv468","article-title":"ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap","volume":"43","author":"Metsalu","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0215","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00018-008-8532-1","article-title":"Nuclear functions of heterogeneous nuclear ribonucleoproteins A\/B","volume":"66","author":"He","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jprot.2020.103813_bb0220","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jpsychires.2010.04.014","article-title":"Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia","volume":"44","author":"Martins-de-Souza","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0225","first-page":"37","article-title":"The nuclear proteome of white and Gray matter from schizophrenia Postmortem brains","volume":"3","author":"Saia-Cereda","year":"2017","journal-title":"Mol Neuropsychiatr."},{"key":"10.1016\/j.jprot.2020.103813_bb0230","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1074\/jbc.M209764200","article-title":"Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase","volume":"278","author":"Teufel","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jprot.2020.103813_bb0235","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jpsychires.2013.07.021","article-title":"Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters","volume":"47","author":"Maccarrone","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0240","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajmg.b.32638","article-title":"Machine learning in schizophrenia genomics, a case-control study using 5,090 exomes","volume":"180","author":"Trakadis","year":"2019","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.jprot.2020.103813_bb0245","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1186\/s12864-019-5848-1","article-title":"The difference in serum proteomes in schizophrenia and bipolar disorder","volume":"20","author":"Smirnova","year":"2019","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jprot.2020.103813_bb0250","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jprot.2020.103813_bb0255","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4161\/epi.7.2.18910","article-title":"Epigenetic and genetic variation at the IGF2\/H19 imprinting control region on 11p15.5 is associated with cerebellum weight","volume":"7","author":"Pidsley","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.jprot.2020.103813_bb0260","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41467-019-09786-7","article-title":"Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis","volume":"10","author":"Pai","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jprot.2020.103813_bb0265","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature09667","article-title":"A critical role for IGF-II in memory consolidation and enhancement","volume":"469","author":"Chen","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jprot.2020.103813_bb0270","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.12151","article-title":"Retrograde fibroblast growth factor 22 (FGF22) signaling regulates insulin-like growth factor 2 (IGF2) expression for activity-dependent synapse stabilization in the mammalian brain","volume":"5","author":"Terauchi","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.jprot.2020.103813_bb0275","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0896-6273(00)80883-1","article-title":"Piccolo, a presynaptic zinc finger protein structurally related to bassoon","volume":"25","author":"Fenster","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.jprot.2020.103813_bb0280","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0959-4388(00)00093-3","article-title":"Molecular determinants of presynaptic active zones","volume":"10","author":"Garner","year":"2000","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.jprot.2020.103813_bb0285","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.mcn.2005.09.013","article-title":"Altered gene expression in the amygdala in schizophrenia: up-regulation of genes located in the cytomatrix active zone","volume":"31","author":"Weidenhofer","year":"2006","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.jprot.2020.103813_bb0290","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jpsychires.2008.04.001","article-title":"Investigation of the expression of genes affecting cytomatrix active zone function in the amygdala in schizophrenia: effects of antipsychotic drugs","volume":"43","author":"Weidenhofer","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0295","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature16549","article-title":"Schizophrenia risk from complex variation of complement component 4","volume":"530","author":"Sekar","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jprot.2020.103813_bb0300","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.biopsych.2013.09.018","article-title":"Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis","volume":"75","author":"Corvin","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0305","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","article-title":"Common variants conferring risk of schizophrenia","volume":"460","author":"Stefansson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jprot.2020.103813_bb0310","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1176\/appi.ajp.2017.17030283","article-title":"Psychiatric genomics: an update and an agenda","volume":"175","author":"Sullivan","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0315","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/npp.2017.164","article-title":"Complement gene expression correlates with superior frontal cortical thickness in humans","volume":"43","author":"Allswede","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jprot.2020.103813_bb0320","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.91","article-title":"Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset","volume":"5","author":"Chan","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0330","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/schbul\/sbu099","article-title":"Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project","volume":"41","author":"Perkins","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jprot.2020.103813_bb0335","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0340","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/npp.2016.102","article-title":"Repeated social defeat, Neuroinflammation, and behavior: monocytes carry the signal","volume":"42","author":"Weber","year":"2016","journal-title":"Neuropsychopharmacol. Rev."},{"key":"10.1016\/j.jprot.2020.103813_bb0345","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/npp.2016.122","article-title":"Central nervous system: (immunological) ivory tower or not?","volume":"42","author":"Marin","year":"2016","journal-title":"Neuropsychopharmacol. Rev."},{"key":"10.1016\/j.jprot.2020.103813_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2008.12.006","article-title":"Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice","author":"Sugino","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.jprot.2020.103813_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2007.01.019","article-title":"Risperidone significantly inhibits interferon-\u03b3-induced microglial activation in vitro","author":"Kato","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0360","first-page":"1","article-title":"An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis","author":"\u00c7akici","year":"2019","journal-title":"Psychol Med"},{"key":"10.1016\/j.jprot.2020.103813_bb0365","first-page":"1","article-title":"Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment","author":"Steiner","year":"2019","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jprot.2020.103813_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030876","article-title":"Within the brain: the renin angiotensin system","volume":"19","author":"Jackson","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jprot.2020.103813_bb0375","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ijcard.2012.10.007","article-title":"The past, present and future of renin-angiotensin aldosterone system inhibition","volume":"167","author":"Mentz","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jprot.2020.103813_bb0380","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease","volume":"26","author":"Perez-Lloret","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jprot.2020.103813_bb0385","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10571-015-0285-4","article-title":"Neurovascular and cognitive failure in Alzheimer\u2019s disease: benefits of cardiovascular therapy","volume":"36","author":"Hamel","year":"2016","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.jprot.2020.103813_bb0390","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/phar.1968","article-title":"Cardiovascular pharmacogenomics and cognitive function in patients with schizophrenia","volume":"37","author":"Ward","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jprot.2020.103813_bb0395","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00406-011-0283-6","article-title":"Differential phosphorylation of serum proteins reflecting inflammatory changes in schizophrenia patients","volume":"262","author":"Jaros","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jprot.2020.103813_bb0400","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.2741\/2275","article-title":"SERPINA3 (aka alpha-1-antichymotrypsin)","volume":"12","author":"Baker","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.jprot.2020.103813_bb0405","article-title":"Increased levels of midbrain immune-related transcripts in schizophrenia and in murine offspring after maternal immune activation","author":"Purves-Tyson","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0410","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.biopsych.2013.05.031","article-title":"High white matter neuron density with elevated cortical cytokine expression in schizophrenia","volume":"75","author":"Fung","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0415","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/mp.2016.90","article-title":"Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review","volume":"21","author":"Tr\u00e9panier","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0420","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00406-008-0847-2","article-title":"Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia","volume":"259","author":"Martins-de-Souza","year":"2009","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jprot.2020.103813_bb0425","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.238","article-title":"Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation","volume":"6","author":"Zhang","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0430","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00406-004-0478-1","article-title":"COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy","volume":"254","author":"M\u00fcller","year":"2004","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jprot.2020.103813_bb0435","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/schbul\/sbt139","article-title":"Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update","volume":"40","author":"Sommer","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jprot.2020.103813_bb0440","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jprot.2020.103813_bb0445","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/09540260600581993","article-title":"Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia","volume":"18","author":"Mahadik","year":"2006","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0450","doi-asserted-by":"crossref","unstructured":"Reddy RD, Yao JK. Free radical pathology in schizophrenia: A review. Prostaglandins Leukotrienes and Essential Fatty Acids doi:https:\/\/doi.org\/10.1016\/S0952-3278(96)90143-X.","DOI":"10.1016\/S0952-3278(96)90143-X"},{"key":"10.1016\/j.jprot.2020.103813_bb0455","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000077368","article-title":"Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics","volume":"49","author":"Dakhale","year":"2004","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.jprot.2020.103813_bb0460","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00406-016-0749-7","article-title":"Oxidative stress in drug-na\u00efve first episode patients with schizophrenia and major depression: effects of disease acuity and potential confounders","volume":"268","author":"Jordan","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jprot.2020.103813_bb0465","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ajmg.b.32638","article-title":"Machine learning in schizophrenia genomics, a case-control study using 5,090 exomes","volume":"180","author":"Trakadis","year":"2019","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"10.1016\/j.jprot.2020.103813_bb0470","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00213-005-0117-1","article-title":"Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia","volume":"182","author":"Dakhale","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jprot.2020.103813_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/S0920-9964(02)00284-0","article-title":"Supplementation with a combination of \u03c9-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia","author":"Arvindakshan","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0480","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41398-018-0266-8","article-title":"N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial","volume":"8","author":"Klauser","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0485","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/sj.npp.1301624","article-title":"Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients","volume":"33","author":"Lavoie","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jprot.2020.103813_bb0490","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement Cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jprot.2020.103813_bb0495","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fpsyt.2019.00573","article-title":"Emerging roles of complement in psychiatric disorders","volume":"10","author":"Druart","year":"2019","journal-title":"Front Psychiatr."},{"key":"10.1016\/j.jprot.2020.103813_bb0500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186414","article-title":"Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus","volume":"12","author":"Asano","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jprot.2020.103813_bb0505","doi-asserted-by":"crossref","DOI":"10.1172\/JCI27883","article-title":"Liver X receptors as integrators of metabolic and inflammatory signaling","volume":"116","author":"Zelcer","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jprot.2020.103813_bb0510","article-title":"RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of A\u03b2 oligomers OPEN","author":"Nyon Nam","year":"2016","journal-title":"Nat Publ Gr"},{"key":"10.1016\/j.jprot.2020.103813_bb0515","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/WNF.0b013e31806450da","article-title":"Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial","volume":"31","author":"Lerner","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jprot.2020.103813_bb0520","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.12m08160","article-title":"The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial","volume":"74","author":"Lerner","year":"2013","journal-title":"J Clin Psychiatr"},{"key":"10.1016\/j.jprot.2020.103813_bb0525","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.schres.2004.03.001","article-title":"Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics","volume":"72","author":"Sharma","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jprot.2020.103813_bb0530","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1073\/pnas.95.13.7240","article-title":"Three independent lines of evidence suggest retinoids as causal to schizophrenia","volume":"95","author":"Goodman","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jprot.2020.103813_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2012.05.027","article-title":"Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls","volume":"76","author":"Jaros","year":"2012","journal-title":"J Proteomics"},{"key":"10.1016\/j.jprot.2020.103813_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2017.10.008","article-title":"Fibrinogen activates BMP signaling in oligodendrocyte progenitor cells and inhibits remyelination after vascular damage","author":"Petersen","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.jprot.2020.103813_bb0545","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1111\/j.1582-4934.2008.00434.x","article-title":"A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer\u2019s disease brain","volume":"13","author":"Ryu","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.jprot.2020.103813_bb0550","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s11606-014-2784-2","article-title":"Outcomes of anticoagulation therapy in patients with mental health conditions","volume":"29","author":"Paradise","year":"2014","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jprot.2020.103813_bb0555","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.204","article-title":"Dysfunction in the coagulation system and schizophrenia","volume":"6","author":"Hoirisch-Clapauch","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jprot.2020.103813_bb0560","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/schbul\/sby113","article-title":"Neutrophil count is associated with reduced Gray matter and enlarged ventricles in first-episode psychosis","volume":"45","author":"N\u00fa\u00f1ez","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jprot.2020.103813_bb0565","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201800173","article-title":"Plasma proteomics analysis reveals dysregulation of complement proteins and inflammation in acquired obesity-A study on rare BMI-discordant monozygotic twin pairs","volume":"13","author":"Sahebekhtiari","year":"2019","journal-title":"Proteomics Clin Appl"},{"key":"10.1016\/j.jprot.2020.103813_bb0570","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/schbul\/sbx075","article-title":"Blood-based protein changes in childhood are associated with increased risk for later psychotic disorder: evidence from a nested case-control study of the ALSPAC longitudinal birth cohort","volume":"44","author":"English","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jprot.2020.103813_bb0575","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/bjc.2017.172","article-title":"Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics","volume":"117","author":"Saraswat","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jprot.2020.103813_bb0580","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/pmic.201200563","article-title":"Assessment of reproducibility in depletion and enrichment workflows for plasma proteomics using label-free quantitative data-independent LC-MS","volume":"14","author":"Hakimi","year":"2014","journal-title":"Proteomics"},{"key":"10.1016\/j.jprot.2020.103813_bb0585","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gkv1145","article-title":"2016 update of the PRIDE database and its related tools","volume":"44","author":"Vizca\u00edno","year":"2016","journal-title":"Nucleic Acids Res."}],"container-title":["Journal of Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391920301810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874391920301810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:01:56Z","timestamp":1778828516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874391920301810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":117,"alternative-id":["S1874391920301810"],"URL":"https:\/\/doi.org\/10.1016\/j.jprot.2020.103813","relation":{},"ISSN":["1874-3919"],"issn-type":[{"value":"1874-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jprot.2020.103813","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103813"}}